Trials / Active Not Recruiting
Active Not RecruitingNCT06541665
Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL
A Multicenter, Phase I, Open-label, Uncontrolled Study of ONO-4059 in Combination With Rituximab, Methotrexate, Procarbazine, and Vincristine (R-MPV) Therapy for Untreated Primary Central Nervous System Lymphoma (PCNSL)
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Ono Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To confirm the tolerability and safety of combined administration of ONO-4059 and R-MPV therapy in untreated PCNSL patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ONO-4059 | Specified dose, once daily |
| DRUG | Rituximab | Specified dose on specified days |
| DRUG | Methotrexate | Specified dose on specified days |
| DRUG | Procarbazine | Specified dose on specified days |
| DRUG | Vincristine | Specified dose on specified days |
Timeline
- Start date
- 2024-05-17
- Primary completion
- 2028-04-28
- Completion
- 2028-08-31
- First posted
- 2024-08-07
- Last updated
- 2025-06-03
Locations
44 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT06541665. Inclusion in this directory is not an endorsement.